Neutral endopeptidase protein expression and prognosis in localized prostate cancer

Clinical Cancer Research

Volumn 10, Issue 12 I, 2004, Pages 4096-4100

  Osman, Iman ^a,b,c   Yee, Herman ^a   Taneja, Samir S ^a,b   Levinson, Benjamin ^a   Zeleniuch Jacquotte, Anne ^a,b   Chang, Caroline ^a   Nobert, Craig ^b   Nanus, David M ^b  

^a NEW YORK UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; GROWTH FACTOR; MEMBRANE METALLOENDOPEPTIDASE; NEUROPEPTIDE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; DNA METHYLATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; RACE; TUMOR VOLUME;

DISEASE PROGRESSION; DNA METHYLATION; DOWN-REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; NEPRILYSIN; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 3042668080     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0120     Document Type: Article

References (18)

1. Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001;12 Suppl 2:S145-52.
2. Nelson JB, Carducci MA. Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer. Cancer Invest 2000;18:87-96.
3. Rozengurt E. Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists. J Cell Physiol 1998;177:507-17.
4. Sumitomo M, Shen R, Walburg M, et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. J Clin Investig 2000;106:1399-407.
5. Sumitomo M, Milowsky MI, Shen R, et al. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res 2001;61:3294-8.
6. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
7. Papandreou CN, Usmani B, Geng Y, et al. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 1998;4:50-7.
8. Usmani BA, Shen R, Janeczko M, et al. Methylation of the neutral endopeptidase gene promoter in human prostate cancers. Clin Cancer Res 2000;6:1664-70.
9. Polsky D, Melzer K, Hazan C, et al. HDM2 protein overexpression and prognosis in primary malignant melanoma. J Natl Cancer Inst 2002;94:1803-6.
10. Osman I, Sherman E, Singh B, et al. Alteration of p53 pathway in squamous cell carcinoma of the head and neck: impact on treatment outcome in patients treated with larynx preservation intent. J Clin Oncol 2002;20:2980-7.
11. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000;6:1891-5.
12. Osman I, Scher HI, Drobnjak M, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001;7:2643-7.
13. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 1999;5:2082-8.
14. Cordon-Cardo C, Koff A, Drobnjak M, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-91.
15. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-6.
16. Simon, R. Evaluating prognostic factor studies. In: M. K. Gospodarowicz (ed.), Prognostic Factors in Cancer, Ed. 2. New York: Wiley-Liss, Inc., 2001.
17. Freedland SJ, Seligson DB, Liu AY, et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003;55:71-80.
18. Zellweger T, Ninck C, Mirlacher M, et al. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003;55:20-9.